News Brief

Neusoft Wins First China Approval for Photon-Counting CT, Launches NeuViz P10

Published Date: August 28, 2025
By News Release

Neusoft Medical Systems has announced that its NeuViz P10 photon-counting CT scanner has received market approval from the National Medical Products Administration (NMPA), making it the first photon-counting CT approved in China. It is also the world’s first wide-body system equipped with an 8-centimeter detector, signaling a major advance in next-generation imaging technology.

Photon-counting CT (PCCT) is widely regarded as a breakthrough in medical imaging. Unlike conventional CT scanners, which convert X-rays into visible light before producing digital images, the NeuViz P10 employs a cadmium zinc telluride (CZT) detector that captures each X-ray photon directly and converts it into a digital signal. This direct approach enhances clarity, reduces patient radiation dose, and improves the ability to differentiate between tissues.

For patients, the technology translates into clearer visualization of small blood vessels in the heart, earlier detection of tiny tumors, more accurate assessment of neurological conditions, and safer lung examinations with less radiation exposure. Its ultra-high-resolution imaging may allow clinicians to identify disease at earlier stages, when interventions are most effective and patient outcomes are significantly improved.

To maximize both clinical and research applications, the NeuViz P10 integrates four dedicated innovation platforms:

  • NeuPhoton Counting, focused on direct photon capture and ultra-clear imaging.

  • Photon Supersonic, delivering faster scan speeds with optimized efficiency.

  • Photon Intelligence, offering AI-powered workflow support to streamline use in busy clinical environments.

  • Photon Research, providing new avenues for advanced clinical studies and imaging innovation.

Together, these platforms enable faster and safer imaging, intelligent decision support, and expanded opportunities for both healthcare providers and researchers.

“The approval of NeuViz P10 is a milestone for China’s medical imaging industry and for global CT innovation,” said Patrick Wu, CEO of Neusoft Medical Systems. “This technology empowers radiologists with clearer images at lower doses, giving patients earlier and more accurate answers while delivering maximum clinical value for public health.”

The approval underscores the rapid momentum of photon-counting CT as a transformative technology in diagnostic imaging. By combining higher resolution with lower radiation exposure, the NeuViz P10 is poised to improve clinical outcomes across specialties including cardiology, oncology, pulmonology, and neurology. It also positions China at the forefront of PCCT deployment, with the potential to influence adoption trends globally.

As health systems worldwide face increasing demands for early diagnosis, precision medicine, and patient safety, innovations like the NeuViz P10 could play a pivotal role in reshaping CT imaging standards. With its approval, Neusoft takes a leadership step in advancing PCCT from research to real-world practice, offering new tools for radiologists and new hope for patients.